

Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 525392-00020 8.0 2024/09/28 Date of first issue: 2016/02/23

1. PRODUCT AND COMPANY IDENTIFICATION

Pembrolizumab Solid Formulation Chemical product name

Supplier's company name, address and phone number

Company name of supplier MSD

Address Kumagaya, Saitama Prefecture, Xicheng 810 MSD Co., Ltd.

Menuma factory

Telephone 048-588-8411

E-mail address EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use **Pharmaceutical** Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

Reproductive toxicity Category 1B

repeated exposure (Oral)

Specific target organ toxicity - : Category 1 (Immune system)

GHS label elements

Hazard pictograms

Signal word

Hazard statements H360D May damage the unborn child.

H372 Causes damage to organs (Immune system) through

prolonged or repeated exposure if swallowed.

Precautionary statements Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Important symptoms and outlines of the emergency assumed

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Sucrose	57-50-1	>= 70 - < 80	-
Pembrolizumab	1374853-91-4	>= 20 - < 30	-

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

May damage the unborn child.

Causes damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Protection of first-aiders

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

so

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.



Pembrolizumab Solid Formulation

Version Date of last issue: 2024/04/06 Revision Date: SDS Number: 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Do not get on skin or clothing. Advice on safe handling

> Do not breathe dust. Do not swallow. Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact

Oxidizing agents

If exposure to chemical is likely during typical use, provide eye Hygiene measures

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

Storage

Keep in properly labelled containers. Conditions for safe storage

> Store locked up. Keep tightly closed.



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m3	ACGIH
Pembrolizumab	1374853-91- 4	TWA	450 μg/m3 (OEB 2)	Internal

Engineering measures : Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Eye protection : Wear the following personal protective equipment:

Safety goggles

Skin and body protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective



Pembrolizumab Solid Formulation

Version **Revision Date:** 8.0 2024/09/28

SDS Number: 525392-00020 Date of last issue: 2024/04/06 Date of first issue: 2016/02/23

clothing (gloves, aprons, boots, etc).

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state powder

Colour white to off-white

Odour No data available

Odour Threshold No data available

Melting point/freezing point No data available

Boiling point, initial boiling point and boiling range

No data available

Flammability (solid, gas) May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Up- : No data available

per flammability limit

Lower explosion limit / Lower flammability limit

No data available

Flash point Not applicable

Decomposition temperature No data available

pΗ No data available

Evaporation rate No data available

Auto-ignition temperature No data available

Viscosity

No data available Viscosity, dynamic

Viscosity, kinematic No data available

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

No data available

No data available Vapour pressure

Density and / or relative density



Pembrolizumab Solid Formulation

Version SDS Number: Date of last issue: 2024/04/06 **Revision Date:** 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Relative density No data available

Density No data available

No data available Relative vapour density

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle characteristics

Particle size No data available

10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

tions

Possibility of hazardous reac- : May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Hazardous decomposition

products

Oxidizing agents No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of: Inhalation

exposure

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Sucrose:

Acute oral toxicity LD50 (Rat): 29,700 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

Sucrose:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage the unborn child.

Components:

Pembrolizumab:

Reproductive toxicity - As-

sessment

May damage the unborn child., Based on data from similar

materials

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Immune system) through prolonged or repeated exposure if swallowed.

Components:

Pembrolizumab:

Target Organs : Immune system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Pembrolizumab:

Species : Monkey
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d

Remarks : No significant adverse effects were reported



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Species : Dog
NOAEL : 200 mg/kg
Application Route : Intravenous
Exposure time : 180 d

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Pembrolizumab:

Inhalation : Target Organs: Immune system

Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis

Remarks: Damage to fetus possible

12. ECOLOGICAL INFORMATION

Ecotoxicity

No data available

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Sucrose:

Partition coefficient: n- : Pow: < 1

octanol/water

Mobility in soil

No data available

Hazardous to the ozone layer

Not applicable

Other adverse effects

No data available



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen: Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Proper shipping name Not applicable Not applicable Class Not applicable Subsidiary risk Packing group Not applicable Labels Not applicable **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

Not applicable



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Not applicable to dangerous materials / designated flammables.

Chemical Substance Control Law

Not applicable for Specified Chemical Substance, Monitoring Chemical Substance and Priority Assessment Chemical Substance.

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Not applicable

Substances Subject to be Indicated Names

Not applicable

Skin and Eye Damage Substances for PPE Requirements (ISHL MO Art. 594-2)

Not applicable

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Not regulated as a dangerous good

Aviation Law

Not regulated as a dangerous good

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Not classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.



Pembrolizumab Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 8.0 2024/09/28 525392-00020 Date of first issue: 2016/02/23

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN